Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

William Blair initiated coverage on Natera Inc. (NASDAQ:NTRA), highlighting the company's strong positioning in the emerging minimal residual disease (MRD) testing market and its broader growth outlook driven by multiple business segments.